COMT and MTHFR polymorphisms interaction on cognition in schizophrenia: An exploratory study

Neuroscience Letters

Volumn 537, Issue , 2013, Pages 17-22

  Kontis, Dimitrios ^a   Theochari, Eirini ^a   Fryssira, Helen ^b   Kleisas, Spyridon ^a   Sofocleous, Christalena ^c   Andreopoulou, Angeliki ^a   Kalogerakou, Stamatina ^b   Gazi, Anthia ^a   Boniatsi, Lucia ^a   Chaidemenos, Alexandros ^a   Tsaltas, Eleftheria ^b  

^a Psychiatric Hospital of Attika Dafni   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Children's Hospital Aghia Sophia   (Greece)

Author keywords

CANTAB; Cognition; COMT; Interaction; MTHFR; Schizophrenia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CATECHOL METHYLTRANSFERASE; NEUROLEPTIC AGENT; VALINE;

ADULT; ALLELE; ARTICLE; ATTENTION; COGNITION; CONTROLLED STUDY; EDUCATIONAL STATUS; ENZYME POLYMORPHISM; EXECUTIVE FUNCTION; EXPLORATORY RESEARCH; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PATHOGENESIS; PRIORITY JOURNAL; PROBLEM SOLVING; PSYCHOMOTOR PERFORMANCE; RECOGNITION; SCHIZOPHRENIA; SPATIAL MEMORY; WORKING MEMORY;

ADULT; ATTENTION; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MEMORY; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; PSYCHOMOTOR PERFORMANCE; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84874354263     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.01.012     Document Type: Article

References (38)

1. Apud J.A., Weinberger D.R. Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors. CNS Drugs 2007, 21:535-557.
2. Barnett J.H., Jones P.B., Robbins T.W., Muller U. Effects of the catechol-O-methyltransferase Val158Met polymorphism on executive function: a meta-analysis of the Wisconsin Card Sort Test in schizophrenia and healthy controls. Molecular Psychiatry 2007, 12:502-509.
3. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. American Journal of Human Genetics 2004, 75:807-821.
4. Davis J.M., Chen N. Dose-response and dose equivalence of antipsychotics. Journal of Clinical Psychopharmacology 2004, 24:192-208.
5. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., Goldman D., Weinberger D.R. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:6917-6922.
6. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J., den Heijer M., Kluijtmans L.A., van den Heuvel L.P., Rozen R. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995, 10:111-113.
7. Goldman D., Weinberger D.R., Malhotra A.K., Goldberg T.E. The role of COMT Val158Met in cognition. Biological Psychiatry 2009, 65:e1-e2. (author reply e3-e4).
8. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. American Journal of Psychiatry 1996, 153:321-330.
9. Harvey P.D., Green M.F., Bowie C., Loebel A. The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements. Psychopharmacology 2006, 187:356-363.
10. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12:426-445.
11. Henry J.D., Crawford J.R. A meta-analytic review of verbal fluency deficits in schizophrenia relative to other neurocognitive deficits. Cognitive Neuropsychiatry 2005, 10:1-33.
12. Jacques P.F., Bostom A.G., Williams R.R., Ellison R.C., Eckfeldt J.H., Rosenberg I.H., Selhub J., Rozen R. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996, 93:7-9.
13. Joober R., Gauthier J., Lal S., Bloom D., Lalonde P., Rouleau G., Benkelfat C., Labelle A. Catechol-O-methyltransferase Val-108/158-Met gene variants associated with performance on the Wisconsin Card Sorting Test. Archives of General Psychiatry 2002, 59:662-663.
14. Keefe R.S., Bilder R.M., Harvey P.D., Davis S.M., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Miller D.D., Canive J.M., Adler L.W., Manschreck T.C., Swartz M., Rosenheck R., Perkins D.O., Walker T.M., Stroup T.S., McEvoy J.P., Lieberman J.A. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006, 31:2033-2046.
15. Kimura D. Sex hormones influence human cognitive pattern. Neuro Endocrinology Letters 2002, 23(Suppl. 4):67-77.
16. Kontis D., Theochari E., Kleisas S., Kalogerakou S., Andreopoulou A., Psaras R., Makris Y., Karouzos C., Tsaltas E. Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2010, 34:1333-1341.
17. Laws K.R. A meta-analytic review of Wisconsin Card Sort studies in schizophrenia: general intellectual deficit in disguise?. Cognitive Neuropsychiatry 1999, 4:1-30. (discussion 31-35).
18. Levaux M.N., Potvin S., Sepehry A.A., Sablier J., Mendrek A., Stip E. Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB. European Psychiatry 2007, 22:104-115.
19. McGuffin P., Farmer A., Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Archives of General Psychiatry 1991, 48:764-770.
20. Mudd S.H., Levy H.L., Kraus J.P. Disorders of transsulfuration. The Metabolic and Molecular Base of Inherited Disease 2001, 2007-2056. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
21. Owens S.F., Rijsdijk F., Picchioni M.M., Stahl D., Nenadic I., Murray R.M., Toulopoulou T. Genetic overlap between schizophrenia and selective components of executive function. Schizophrenia Research 2011, 127:181-187.
22. Reichenberg A. The assessment of neuropsychological functioning in schizophrenia. Dialogues in Clinical Neuroscience 2010, 12:383-392.
23. Robbins T.W., James M., Owen A.M., Sahakian B.J., Lawrence A.D., McInnes L., Rabbitt P.M. A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. Cambridge Neuropsychological Test Automated Battery. Journal of the International Neuropsychological Society 1998, 4:474-490.
24. Roffman J.L., Gollub R.L., Calhoun V.D., Wassink T.H., Weiss A.P., Ho B.C., White T., Clark V.P., Fries J., Andreasen N.C., Goff D.C., Manoach D.S. MTHFR 677 C→T genotype disrupts prefrontal function in schizophrenia through an interaction with COMT 158Val→Met. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:17573-17578.
25. Roffman J.L., Weiss A.P., Deckersbach T., Freudenreich O., Henderson D.C., Purcell S., Wong D.H., Halsted C.H., Goff D.C. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schizophrenia Research 2007, 92:181-188.
26. Roffman J.L., Weiss A.P., Deckersbach T., Freudenreich O., Henderson D.C., Wong D.H., Halsted C.H., Goff D.C. Interactive effects of COMT Val108/158Met and MTHFR C677 T on executive function in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 2008, 147B:990-995.
27. Sasaki M., Kaneuchi M., Sakuragi N., Dahiya R. Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer. Cancer Research 2003, 63:3101-3106.
28. Sheldrick A.J., Krug A., Markov V., Leube D., Michel T.M., Zerres K., Eggermann T., Kircher T. Effect of COMT Val158Met genotype on cognition and personality. European Psychiatry 2008, 23:385-389.
29. Stahl S.M. Methylated spirits: epigenetic hypotheses of psychiatric disorders. CNS Spectrums 2010, 15:220-230.
30. Sugden C. One-carbon metabolism in psychiatric illness. Nutrition Research Reviews 2006, 19:117-136.
31. Tan H.Y., Callicott J.H., Weinberger D.R. Prefrontal cognitive systems in schizophrenia: towards human genetic brain mechanisms. Cognitive Neuropsychiatry 2009, 14:277-298.
32. Toulopoulou T., Picchioni M., Rijsdijk F., Hua-Hall M., Ettinger U., Sham P., Murray R. Substantial genetic overlap between neurocognition and schizophrenia: genetic modeling in twin samples. Archives of General Psychiatry 2007, 64:1348-1355.
33. Tunbridge E.M., Harrison P.J., Weinberger D.R. Catechol-o-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biological Psychiatry 2006, 60:141-151.
34. Wechsler D. Wechsler Adult Intelligence Scale-III (WAIS-III) 1997, The Psychological Corporation, New York.
35. Weisberg I.S., Jacques P.F., Selhub J., Bostom A.G., Chen Z., Curtis Ellison R., Eckfeldt J.H., Rozen R. The 1298A→C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 2001, 156:409-415.
36. WHO WHO Collaborating Centre for Drug Statistics Methodology: ATC Classification Index with DDDs 2008, World Health Organization, Oslo, Norway.
37. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 2003, 64:663-667.
38. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophrenia Research 2007, 89:211-224.